These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 24637579

  • 1. Cellular and clinical pharmacology of the taxanes docetaxel and paclitaxel--a review.
    de Weger VA, Beijnen JH, Schellens JH.
    Anticancer Drugs; 2014 May; 25(5):488-94. PubMed ID: 24637579
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Pharmacogenetic and Pharmacokinetic Dose Individualization of the Taxane Chemotherapeutic Drugs Paclitaxel and Docetaxel.
    Andriguetti NB, Raymundo S, Antunes MV, Perassolo MS, Verza SG, Suyenaga ES, Linden R.
    Curr Med Chem; 2017 May; 24(33):3559-3582. PubMed ID: 28641556
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Preclinical pharmacologic evaluation of MST-997, an orally active taxane with superior in vitro and in vivo efficacy in paclitaxel- and docetaxel-resistant tumor models.
    Sampath D, Greenberger LM, Beyer C, Hari M, Liu H, Baxter M, Yang S, Rios C, Discafani C.
    Clin Cancer Res; 2006 Jun 01; 12(11 Pt 1):3459-69. PubMed ID: 16740771
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Update on taxane development: new analogs and new formulations.
    Yared JA, Tkaczuk KH.
    Drug Des Devel Ther; 2012 Jun 01; 6():371-84. PubMed ID: 23251087
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effects of paclitaxel, docetaxel and their combinations on subcutaneous lymphomas in inbred Sprague-Dawley/Cub rats.
    Otová B, Václavíková R, Danielová V, Holubová J, Ehrlichová M, Horský S, Soucek P, Simek P, Gut I.
    Eur J Pharm Sci; 2006 Dec 01; 29(5):442-50. PubMed ID: 17000091
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Docetaxel and ifosfamide in patients with advanced solid tumors: results of a phase I study.
    Pronk LC, Schrijvers D, Schellens JH, de Bruijn EA, Planting AS, Locci-Tonelli D, Groult V, Verweij J, van Oosterom AT.
    Semin Oncol; 1998 Feb 01; 25(1 Suppl 2):23-8. PubMed ID: 9535208
    [Abstract] [Full Text] [Related]

  • 20. Docetaxel and ketoconazole in advanced hormone-refractory prostate carcinoma: a phase I and pharmacokinetic study.
    Van Veldhuizen PJ, Reed G, Aggarwal A, Baranda J, Zulfiqar M, Williamson S.
    Cancer; 2003 Nov 01; 98(9):1855-62. PubMed ID: 14584067
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.